Overview

Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer

Status:
Completed

Trial end date:
2020-02-01

Target enrollment:

Participant gender:

Summary

This study will be looking at whether gemcitabine, taxotere, and xeloda (GTX) in combination with cisplatin and irinotecan is effective (anti-tumor activity) and safe in patients with metastatic pancreatic cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborator:

Swim Across America Laboratory

Treatments:

Camptothecin
Capecitabine
Cisplatin
Docetaxel
Gemcitabine
Irinotecan